Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with heart failure (HF), but the evidence of their efficacy in patients who have had an acute myocardial infarction (AMI) is still incompletely established. Here, SLC5A2 is linked to heart failure.